• Irfan Ullah Department of Stroke, Nevill Hall Hospital Abergavenny, South Wales-UK
  • Najeebullah Khan Department of Gastroenterology, Northampton General Hospital-UK
  • Bazilina Majid Department of Physiology, Khyber Medical University Peshawar-Pakistan
  • Saira Kainat Awan Kabir Medial College Peshawar
  • Nudrat Gul Lady Reading Hospital Peshawar


Inflammatory Bowel Disease, Ulcerative Colitis, Crohn’s Disease, Methotrexate



A chronic disease of the intestine in genetically susceptible individuals, Inflammatory bowel disease (IBD) is caused by contributing elements of both innate and adaptive immune system. IBD is a group of inflammatory conditions of the bowel that is chronic and uncontrolled in nature. The triggers that start and sustain this constant irritation are the subject of much hypothesis and exploration, in spite of the fact that the focal function of the microbiota (intestinal) is perceived, and is even an objective for treatment in certain conditions. The modern day IBD treatment is targeted at concealing safe reaction towards so far unknown antigens, and customary treatment that includes 5‐aminosalicylic acid (5‐ASA), thiopurines, corticosteroids and methotrexate. Although a complete cure for IBD is not yet available but ongoing revelations in the field of neurosciences and immunology have uncovered that signals in the fringe sensory system direct irritation, including levels of TNF‐α show promising results. Clinical examinations utilizing vagus nerve embedded triggers for IBD treatment show empowering results. As needs be, the reflex control (neural) of aggravation is developing as a possible remedial objective in treating IBD. Here, we audit available and current treatment choices. These include the use 5-ASA, Glucocorticosteroids, Methotrexate and Thiopurines.


Burisch J, Jess T, Martinato M, Lakatos PL, EpiCom E. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322‐337.

Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal anti-inflammatory effect of 5‐aminosalicylic acid is dependent on peroxisome proliferator‐activated receptor‐gamma. J Exp Med. 2005;201:1205‐1215.

Gisbert JP, Gomollon F, Mate J, et al. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. 2002.

Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol. 2007;275:71‐78.

Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50:3408‐3417.

Cronstein B. How does methotrexate suppress inflammation? Clin Exp Rheumatol. 2010;28:S21‐S23.

Herfarth HH, Kappelman MD, Long MD, Isaacs KL. Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016;22(1):224-233.

Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:715‐729.

Neurath M. Thiopurines in IBD: What Is Their Mechanism of Action?. Gastroenterol Hepatol (N Y). 2010;6(7):435-4



How to Cite

Ullah, I., Khan, N., Majid, B., Awan, S. K., & Gul, N. (2020). TREATMENT MODALITIES OF INFLAMMATORY BOWEL DISEASE (IBD). THE STETHO, 1(1), 1-3. Retrieved from

Most read articles by the same author(s)